| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24013 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Pembrolizumab, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung carcinoma (NSCLC) at high risk of recurrence in adults. |
| Assessment Process | |
| Rapid review commissioned | 22/04/2024 |
| Rapid review completed | 16/05/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment of resectable NSCLC, compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/05/2024 |
| Pre-submission consultation with Applicant | 02/07/2024 |
| Full submission received from Applicant | 22/05/2025 |
| Preliminary review sent to Applicant | 23/10/2025 |
| NCPE assessment re-commenced | 28/11/2025 |
| Factual accuracy sent to Applicant | 30/01/2026 |
| NCPE assessment re-commenced | 10/02/2026 |
| NCPE assessment completed | 10/03/2026 |
| NCPE assessment outcome | The NCPE recommends that pembrolizumab, for the indication under assessment, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments* |
*The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the Patient Organisation Submission and the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.